Quantinno Capital Management LP Buys Shares of 38,311 The Chemours Company (NYSE:CC)

Quantinno Capital Management LP bought a new stake in The Chemours Company (NYSE:CC - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 38,311 shares of the specialty chemicals company's stock, valued at approximately $647,000.

A number of other institutional investors also recently bought and sold shares of the company. Quadrant Capital Group LLC raised its stake in shares of Chemours by 100.4% in the fourth quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock worth $38,000 after buying an additional 1,119 shares during the period. Aster Capital Management DIFC Ltd bought a new position in shares of Chemours in the fourth quarter worth about $48,000. Itau Unibanco Holding S.A. raised its stake in shares of Chemours by 39.3% in the fourth quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock worth $60,000 after buying an additional 1,003 shares during the period. KBC Group NV raised its stake in shares of Chemours by 38.2% in the fourth quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock worth $104,000 after buying an additional 1,708 shares during the period. Finally, Sterling Capital Management LLC raised its stake in shares of Chemours by 54.8% in the fourth quarter. Sterling Capital Management LLC now owns 8,453 shares of the specialty chemicals company's stock worth $143,000 after buying an additional 2,991 shares during the period. Institutional investors own 76.26% of the company's stock.

Insider Activity at Chemours

In other Chemours news, CFO Shane Hostetter acquired 4,450 shares of the company's stock in a transaction that occurred on Monday, May 19th. The stock was bought at an average price of $11.28 per share, for a total transaction of $50,196.00. Following the acquisition, the chief financial officer now directly owns 59,694 shares in the company, valued at $673,348.32. The trade was a 8.06% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.34% of the stock is owned by company insiders.

Chemours Trading Down 5.8%

Shares of Chemours stock traded down $0.62 on Wednesday, reaching $10.01. The company had a trading volume of 3,931,201 shares, compared to its average volume of 2,105,785. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of 17.55 and a beta of 1.76. The company has a debt-to-equity ratio of 6.70, a current ratio of 1.68 and a quick ratio of 0.92. The firm's 50-day moving average price is $11.80 and its two-hundred day moving average price is $15.85. The Chemours Company has a 1 year low of $9.33 and a 1 year high of $26.98.

Chemours (NYSE:CC - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). The company had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.36 billion. Chemours had a return on equity of 26.54% and a net margin of 1.51%. Chemours's revenue for the quarter was up .4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.32 EPS. As a group, research analysts predict that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Monday, June 16th. Investors of record on Monday, May 19th will be issued a dividend of $0.0875 per share. This represents a yield of 3.17%. The ex-dividend date of this dividend is Friday, May 16th. Chemours's payout ratio is currently 175.00%.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Barclays cut their target price on Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday. Truist Financial cut their target price on Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Morgan Stanley cut their price target on Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a report on Monday, May 12th. Royal Bank of Canada cut their price target on Chemours from $17.00 to $14.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Finally, BMO Capital Markets cut their price target on Chemours from $34.00 to $27.00 and set an "outperform" rating for the company in a report on Wednesday, February 19th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $17.22.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.